BBIO vs V · rev $221.9M vs P/E 33, rev $40.00B
BridgeBio Pharma Inc (BBIO) versus Visa Inc. Class A (V) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Visa Inc. Class A (V) is a credit services company listed on US. It is led by Ryan McInerney.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported V revenue for 2025-09-30 was $40.00B. Net income was $20.06B. V currently screens at market cap $659.78B and trailing P/E 33.5.
BBIO currently screens at market cap $13.24B. V currently screens at market cap $659.78B and trailing P/E 33.5.
Not investment advice. Open the BBIO and V stock pages for the full models.
Not investment advice.